New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareVesugen vs Epithalon

Vesugen vs Epithalon

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Vesugen
Anti-Aging & Longevity
Epithalon
Summary
Vesugen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for blood vessels and the vascular endothelium. It supports endothelial cell function, promotes vascular wall integrity, and is studied for atherosclerosis prevention, vascular aging, and cardiovascular health maintenance. It is one of the more broadly applicable Khavinson bioregulators given the ubiquity of vascular tissue.
Epithalon is a synthetic tetrapeptide developed from the pineal gland extract Epithalamin by Russian scientist Dr. Vladimir Khavinson. It is one of the most researched longevity peptides, known for activating telomerase and extending telomere length — the molecular hallmarks of cellular aging.
Half-Life
Short (minutes); sustained gene-regulatory effects
2–4 hours
Admin Route
SubQ, Oral
SubQ, Sublingual
Research
Typical Dose
10 mg per day
5–10 mg total per cycle
Frequency
Daily for 10–30 days
0.5–1 mg daily
Key Benefits
  • Supports vascular endothelial cell function and integrity
  • May reduce endothelial inflammation and dysfunction
  • Anti-aging effects on blood vessel walls
  • Potential benefits in early atherosclerosis and vascular aging
  • Supports nitric oxide-mediated vascular tone
  • Reduces endothelial apoptosis from oxidative stress
  • Complementary to Cardiogen and Epithalon in cardiovascular longevity protocols
  • Activates telomerase enzyme, extending telomere length
  • May slow cellular and biological aging
  • Regulates melatonin production and circadian rhythms
  • Improves sleep quality
  • Powerful antioxidant properties
  • May reduce incidence of age-related diseases
  • Supports immune system function
  • Studied for cancer prevention properties in animal models
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant vascular adverse events reported at standard doses
  • Injection site irritation (mild)
  • Temporary sleep changes during cycle (usually improves)
  • Rare: fatigue
Stacks With